


AN ENANTIOSELECTIVE SYNTHESIS OF (+)-CROTANECINE BY AN INTRAMOLECULAR AZIDE [2+3] DIPOLAR CYCLOADDITION

Richard B. Bennett III and Jin K. Cha*
Department of Chemistry, Vanderbilt University, Nashville, TN 37235, U.S.A.

Abstract: An efficient, enantioselective synthesis of (+)-crotanecine (1) has been accomplished by an intramolecular azide [2+3] dipolar cycloaddition starting from 2,3-O-isopropylidene-D-erythrose (8).

As a part of our research objectives directed at development of a general synthetic methodology for functionalized indolizidine and pyrrolizidine alkaloids,¹ we have recently reported a practical, stereoselective synthesis of (-)-swainsonine by an intramolecular azide [2+3] dipolar cycloaddition (IAC).² As outlined in Scheme I, it appeared to us that a tandem use of the IAC reaction and a cyclopropylimine rearrangement³ would provide an efficient route to pyrrolizidine alkaloids. Herein we wish to communicate an efficient, stereospecific synthesis of (+)-crotanecine (1).⁴ Alkaloids containing the pyrrolizidine nucleus such as 1 and 2 have attracted considerable interest because of their diverse biological activity.⁵

Scheme I




Route *a* would provide a conceptually appealing and operationally simple one-pot synthesis of the tricyclic enamine 3b from the cyclopropyl tosylate 5. The latter should be readily available from the Wittig reaction of cyclopropyltriphenylphosphonium bromide with 2,3-O-isopropylidene-D-erythrose (8).⁶ Concern about potential difficulty of installing the hydroxymethyl or carbomethoxy group at the C-1 (pyrrolizidine numbering) position of enamine 3b,⁷ however, led us to undertake route *b*, wherein it could be put into place at an earlier stage (*vide infra*).

As outlined in Scheme II, the requisite starting material **7** was prepared by the Wittig reaction of **8** with (3-tetrahydropyranyloxypropyl)triphenylphosphonium bromide [KN(SiMe₃)₂, THF, -78 → 0 °C] and subsequent treatment with *p*-toluenesulfonyl chloride.⁸ Displacement of the tosyl group in **7** with sodium azide and the concomitant IAC reaction gave the imine **9** in 65% overall yield from **8**.⁹ The carbomethoxylation was then accomplished in 57% yield by sequential treatment of imine **9** at -78 °C with LDA and Mander's reagent¹⁰, or more conveniently, methyl chloroformate. Subsequent deprotection of the tetrahydropyranyl group with PPTS in methanol gave a single alcohol **10** [mp 83–85 °C; $[\alpha]_D^{20} = -113.39^\circ$ (*c* 0.54, CHCl₃)] in 73% yield. The chemical shift of the proton on nitrogen at δ 7.95 is diagnostic for the expected geometry of the vinylogous carbamate double bond. The cyclopropyl imine **4a**, $[\alpha]_D^{20} = -6.20^\circ$ (*c* 1.87, CHCl₃), was then readily prepared in 91% yield by the usual Crossland mesylation procedure.¹¹


Despite several attempts (cat. NH₄Cl, refluxing toluene or xylene) an acid-catalyzed cyclopropylimine rearrangement of **4a** failed to afford any significant amount of the desired product **3a**. The use of DMF as a solvent, on the other hand, gave pyrrole **11** [mp 95–98 °C; IR (CHCl₃) 1699 cm⁻¹; $[\alpha]_D^{20} = -122.2^\circ$ (*c* 0.135, CHCl₃)] in 35% yield (based on 74% conversion), along with a trace amount of **3a**. We believe that the difficulty with which **4a** undergoes the acid-catalyzed rearrangement can be attributed to the unfavorable double bond geometry of the intermediate **6** [¹H NMR(CDCl₃) δ 8.01 (HN)] *vis-a-vis* the requisite **12**.^{3c} Enamide **6** [mp 82–84 °C; $[\alpha]_D^{20} = -116.79^\circ$ (*c* 0.40, CHCl₃)] could be easily prepared by treating **4a** with aqueous HCl in CH₂Cl₂. We note in passing that our result is in marked contrast to the successful rearrangement of a similar cyclopropyl imine previously reported by Pinnick.¹²

Scheme II



Finally, cyclization to the pyrrolizidine skeleton was effected by initial reduction of the double bond in enamide **6**. Thus, treatment with NaBH_3CN in acidic methanol followed by basic workup gave a diastereomeric mixture of amino esters **13** having the $8R$ configuration. Assignment of the stereochemistry of the ring-junction (C-8) methine proton was based on the expected hydride delivery from the *convex* face and was subsequently confirmed by the eventual conversion to **1**. Subsequent reaction with diphenyl diselenide proceeded uneventfully to give α -selenoester **14**, $[\alpha]_{\text{D}}^{20} = -69.82^\circ$ (*c* 1.11, CHCl_3), in 56% isolated yield. Conversion of the latter to the dehydropyrrolizidine derivative **15**, $[\alpha]_{\text{D}}^{20} = +52.10^\circ$ (*c* 0.19, CHCl_3), was achieved in 47% (95% based on recovered **14**) yield by the procedure reported by Vedejs for retronecine (**2**): protonation of the amine nitrogen, followed by the usual selenium oxidation (mCPBA) and thermal elimination.¹³ The synthesis was then completed by DIBAL-H reduction and subsequent acidic hydrolysis to afford crotonecine (**1**) in 76% overall yield: the ^1H NMR spectrum (in CD_3OD) of synthetic **1** was identical with that of natural material.¹⁴ Its optical rotation and the melting point also were found to be comparable to the literature values $[\alpha]_{\text{D}} = +34.5^\circ$ (*c* 0.055, EtOH); mp $188\text{--}190^\circ\text{C}$ [lit. mp $202\text{--}203.5^\circ\text{C}^{4a}$; 192°C^{4b} ; $[\alpha]_{\text{D}}^{20} = +39.2^\circ$ (*c* 1.3, EtOH)^{4b}].

Scheme III



In summary, a short and enantioselective synthesis of crotonecine (**1**) has been achieved by the intramolecular azide dipolar cycloaddition.¹⁵ Further synthetic applications of the strategy delineated above to other indolizidine and pyrrolizidine alkaloids will be reported in due course.

ACKNOWLEDGMENT Financial support from the National Institutes of Health (GM 35956) is gratefully acknowledged. R. B. B. thanks the Dorothy Danforth Compton Foundation for a fellowship. We also thank the NIH (BRSR RR07201) for partial support toward the purchase of a polarimeter. We are indebted to Professor M. Benn for providing the reference ^1H NMR and IR spectra of natural crotonecine.

References and Footnotes

- For recent general reviews, see (a) Robins, D. J. *Fortshr. Chem. org. Naturst.* **1981**, *41*, 115. (b) Howard, A. S.; Michael, J. P. In *The Alkaloids*; Brossi, A., Ed.; 1986; Vol. 28, pp. 183-308. (c) Rajeswari, S.; Chandrasekharan, S.; Govindachari, T. R. *Heterocycles* **1987**, *25*, 659. (d) Ikeda, M.; Sato, T.; Ishibashi, H. *Heterocycles* **1988**, *27*, 1465.
- Bennett, R. B. III; Choi, J.-R.; Montgomery, W. D.; Cha, J. K. *J. Am. Chem. Soc.* **1989**, *110*, 2580.
- (a) Stevens, R. V. *Acc. Chem. Res.* **1977**, *10*, 193. See also (b) Wasserman, H. H.; Dion, R. P. *Tetrahedron Lett.* **1982**, *23*, 1413 and **1983**, *24*, 3409. Wasserman, H. H.; Dion, R. P.; Fukuyama, J. *Tetrahedron* **1989**, *45*, 3203. (c) Boeckman, R. K. Jr.; Jackson, P. F.; Sabatucci, J. P. *J. Am. Chem. Soc.* **1985**, *107*, 2191. Boeckman, R. K. Jr.; Goldstein, S. W.; Walters, M. A. *Ibid.* **1988**, *110*, 8250.
- Isolation: (a) Atal, C. K.; Kapur, K. K.; Culvenor, C. C. J.; Smith, L. W. *Tetrahedron Lett.* **1966**, 537. (b) Mattocks, A. R. *J. Chem. Soc. (C)* **1968**, 235. Enantioselective Synthesis: (c) Yadav, V. K.; Benn, M. *Heterocycles* **1984**, *22*, 2735. (d) Buchanan, J. G.; Jigajinni, V. B.; Singh, G.; Wightman, R. H. *J. Chem. Soc. Per I* **1987**, 2377.
- Biological Activity: (a) Atal, C. K. *Lloydia*, **1978**, *41*, 312. (b) Mattocks, A. R. *Chemistry and Toxicology of the Pyrrolizidine Alkaloids*; Academic Press: London, 1986. For recent enantioselective syntheses of pyrrolizidines, see *inter alia*: (c) Hart, D. J.; Yang, T.-K. *J. Org. Chem.* **1985**, *50*, 235. (d) Chamberlin, A. R.; Chung, J. Y. L. *Ibid.* **1985**, *50*, 4425. (e) Keck, G. E.; Cressman, E. N. K.; Enholm, E. J. *Ibid.* **1989**, *54*, 4345. See also (f) Hudlicky, T.; Frazier, J. O.; Seoane, G.; Tiedje, M.; Seoane, A.; Kwart, L. D.; Beal, C. J. *Am. Chem. Soc.* **1986**, *108*, 3755. Hudlicky, T.; Seoane, G.; Lovelace, T. C. *J. Org. Chem.* **1988**, *53*, 2094 and references cited therein.
- Cohen, N.; Banner, B. L.; Laurenzano, A. J.; Carozza, L. *Org. Syntheses* **1984**, *63*, 127.
- (a) Alt, G. H.; Cook, A. G. In *Enamines: synthesis, structure, and reactions*, 2nd ed.; Cook, A. G., Ed.; Marcel Dekker: New York, 1988; pp. 204-219. (b) Shono, T.; Matsumura, Y.; Tsubata, K.; Sugihara, Y. *Tetrahedron Lett.* **1982**, *23*, 1201.
- All new compounds are fully characterized by IR spectra, ^1H and ^{13}C NMR spectra, mass spectra, HRMS, and optical rotations:
(a) **15**: IR 1716 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.25 (s, 3H), 1.32 (s, 3H), 3.03 (dd, $J = 14.2, 3.3$ Hz, 1H), 3.22 (d, $J = 14.2$ Hz, 1H), 3.77 (s, 3H), 4.03 (m, 2H), 4.34 (br s, 1H), 4.75 (m, 2H), 6.73 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) 23.9, 26.1, 51.6, 55.9, 62.2, 74.0, 81.8, 84.2, 112.2, 132.6, 140.3, 163.9. (b) **1**: ^1H NMR [300 MHz, CD_3OD (ref. 3.30)] δ 2.60 (dd, $J = 10.2, 8.8$ Hz, 1H), 3.23 (dd, $J = 6.7, 8.8$ Hz, 1H), 3.38-3.43 (m, 1H), 3.86 (m, $J_{\text{AB}} = 14.8$ Hz, 1H), 4.04 (t, $J = 3.8$ Hz, 1H), 4.15-4.20 (m, 4H), 5.71 (m, 1H); ^{13}C NMR (100 MHz, CD_3OD) 59.3, 59.9, 64.2, 72.4, 74.8, 76.2, 125.5, 140.2.
- For related IAC reactions in natural products synthesis, see (a) ref. 2 and references cited therein. (b) Taber, D. F.; Deker, P. B.; Fales, H. M.; Jones, T. H.; Lloyd, H. A. *J. Org. Chem.* **1988**, *53*, 2968. (c) Heidt, P. C.; Bergmeier, S. C.; Pearson, W. H. *Tetrahedron Lett.* following paper.
- (a) Mander, L. N.; Sethi, P. *Tetrahedron Lett.* **1983**, *24*, 5425. (b) Ziegler, F. E.; Wang, T.-F. *Ibid.* **1985**, *26*, 2291.
- Crossland, R. K.; Servis, K. L. *J. Org. Chem.* **1970**, *35*, 3195.
- Pinnick, H. W.; Chang, Y.-H. *Tetrahedron Lett.* **1979**, 837.
- Vedejs, E.; Larsen, S.; West, F. G. *J. Org. Chem.* **1985**, *50*, 2170.
- Kindly furnished by Professor Michael H. Benn, Department of Chemistry, University of Calgary, Canada.
- Retronecine (**2**) should also be readily available from ester **13** by the γ -lactone formation and subsequent deoxygenation of the superfluous C-6 hydroxyl group. Alternatively, it could be prepared by the route described starting from the commercially available (*R*)-malic acid. This will be the subject of a forthcoming full paper: Bennett, R. B. III; Choi, J.-R.; Cha, J. K. unpublished results.